knowledge -WSS

knowledge

author：knowledge 2025-09-28 21:06:40 - browse：2

Gavel and Stethoscope due process — District courts will make the first round of decisions soon on challenges to Medicare's drug price negotiation program. APStock

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

District court judges could soon weigh in on the litany of court cases that major companies filed against the government — shedding light on whether drugmakers have any hope of postponing the first parts of the negotiation process, scrapping it entirely, or sending the issue up to the Supreme Court.

It’s a major moment for the Biden administration, too, as the White House ramps up its efforts to take credit for the new changes in the 2024 election. The first round of legal decisions will play out in the thick of campaign season, attorneys told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Dexcom's push to bring CGM to type 2 diabetes patients

WSS

How are insurers handling Leqembi and related scans?

Inflation cooled significantly in June, bringing price hikes close to normal levels

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Dexcom's push to bring CGM to type 2 diabetes patients

Companies helping big Covid

Security flaws in third

entertainment

knowledge

entertainment

Jerome Adams on the need for new antivirals for Covid

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Apple is now the first public company to be valued at $3 trillion

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Hollywood unions extend contract negotiations for actors

China sends large group of warplanes, navy ships towards Taiwan in forceful display

The cancer drug shortage isn’t new — and neither are the solutions

Digital health funding stays low as a new reality sets in

Peter Hotez and the public health issue of online harassment

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

knowledge

Superbugs, antibiotic resistance get scrutiny in congress

A Greenpeace activist is fined for crash

Vermont grapples with historic flooding as more rainstorms head for Northeast

Being 'nonadherent' patient made me a more empathetic doctor

Fatty liver disease was alleviated by Lilly’s ‘triple

UpToDate has a racism problem: Dr. Stanley Goldfarb

focus

leisure time

focus

knowledge